Name Target Discovery Preclinical Clinical
SUT-001 Dystrophin Yes Yes Q4 2019
SUT-002 Undisclosed Yes Yes Q2 2021
SUT-003 Undisclosed Yes No -

Our Holistic Promise:

“We are a patient orientated company that understands the complexity of the all disease manifestations that occur in Duchenne muscular dystrophy. We are striving to provide ‘all-stage’ disease modifying therapeutics to enhance the quality of life for the community and appreciate a multimodal strategy needs to be adopted. Our enhanced gene medicine delivery platform seeks to address these unmet clinical needs.”

Keep Informed

Sign up for future updates

Thank you